Latest Headlines

Latest Headlines

Novartis discount fails to persuade NICE on Afinitor in breast cancer

To win over U.K. cost-effectiveness gatekeepers, Novartis cut Afinitor's price. Unfortunately for the Swiss drugmaker, it didn't work. The National Institute for Health and Care Excellence still turned down a new use for the drug in HER2-negative breast cancer.

NICE denies Pfizer lung cancer drug in final draft guidance

In the past, the U.K.'s cost-effectiveness gatekeeper has shown that it will bend preliminary draft guidance decisions if the price is right. But for Pfizer, which slashed costs on its targeted lung cancer drug Xalkori in hopes of gaining recommendation for its use in Britain's National Health Service, that price wasn't low enough.

U.K. cost watchdogs nix Roche's new breast cancer drug Perjeta

The U.K.'s cost-effectiveness police have turned up their noses at Roche's new breast cancer drug Perjeta. The National Institute for Health and Care Excellence (NICE) says the drug's ability to extend patients' lives is unclear--and that it's far more costly than currently available treatments.

NICE nods for Eylea, Abilify; FDA panel backs new Cimzia use

The regulators have spoken on both sides of the Atlantic. And in both cases, we have winners--and we have losers.

Cost watchdog nixes Pfizer's new CML drug Bosulif

These days, drugmakers almost always offer discounts to get their products cleared by NICE. But even that's not a sure bet for winning approval. Such was the case with Pfizer's Bosulif, rejected today for the treatment of chronic myeloid leukemia (CML).

UPDATED: Celgene hits new bump in extending Revlimid sales

Celgene's blood cancer drug Revlimid was cruising in the first half of 2013. Now, the U.K.'s cost-effectiveness watchdog has put up a roadblock, but some new positive trial data might keep the setback from taking too much wind out of Revlimid's sails.

Cost watchdogs veto Novartis breast cancer med Afinitor

As the FDA approved Afinitor's new breast cancer indication last year, analysts estimated that it could add up to $1.5 billion to Afinitor's peak sales. That's a nice chunk of change to help Novartis make up for Diovan's patent-cliff losses. But the U.K.'s cost-effectiveness watchdogs have another idea.

UPDATED: Sanofi's Zaltrap hits U.K. cost trap

Sanofi's cancer drug Zaltrap has again fallen into a price trap. The cost watchdog in the U.K. said it does not find the benefits of the colorectal cancer drug outweigh its high price.

Bristol-Myers, AstraZeneca win turnabout at NICE for Forxiga

Bristol-Myers Squibb and AstraZeneca persuaded the U.K.'s cost-effectiveness agency to make an about-face on their new diabetes drug Forxiga.

U.K. likely to pay for Avastin despite another NICE rejection

Regulators have again turned down Roche's cancer drug Avastin for payment by the National Health System (NHS), this time for use on a recurrent, advanced ovarian cancer. But that doesn't mean patients won't get it.